Select Medical Holdings' Q2 revenue rises to meet estimates

Select Medical Holdings

31/07/2025 21:44

Overview

Select Medical Q2 revenue grows 4.5% yr/yr, meets analyst expectations

EPS from continuing operations rises 88.2% to $0.32

Adjusted EBITDA for Q2 increases 0.5% to $125.4 mln

Outlook

Select Medical reaffirms 2025 revenue outlook of $5.3 bln to $5.5 bln

Company expects 2025 Adjusted EBITDA between $510 mln and $530 mln

Select Medical forecasts 2025 EPS between $1.09 and $1.19

Result Drivers

REHABILITATION HOSPITALS - Revenue increased 17.2% due to higher patient admissions and occupancy rates

OUTPATIENT REHABILITATION - Revenue grew 3.8% driven by increased patient visits

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
In-line
$1.34 bln
$1.34 bln (6 Analysts)
Q2 EPS
$0.32
Q2 Adjusted EBITDA
$125.40 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Select Medical Holdings Corp is $21.00, about 31% above its July 30 closing price of $14.48

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release: ID:nPn3mrv9Ga

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)